Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

From Interchangeability To Exclusivity: US FDA Looks For Ways To Make Biologics Market More Competitive

Executive Summary

The agency is being urged to help spur biosimilar development and market success by finalizing guidance on interchangeability, enhancing public education efforts, and taking a more forceful approach to combating misinformation, while reference product sponsors want FDA to adopt 'umbrella' exclusivity to encourage innovative changes in novel biologics.

Advertisement

Related Content

Mehta Analysis: Two Pillars of Industry Success Being Shaken
Pfizer's Epogen Biosimilar Retacrit Launches At 33% Off In A US Market Where Amgen's Already Competitive
Pfizer's Epogen Biosimilar Retacrit Launches At 33% Off In A US Market Where Amgen's Already Competitive
10 Things For Pfizer's New CEO To Worry About
Mylan Head Of Biologics Chrys Kokino On Fulphila Launch And US Biosimilars
Mylan Head Of Biologics Chrys Kokino On Fulphila Launch And US Biosimilars
Pfizer Wants FDA To Stop Sponsor Promos From Implying Biosimilars Are Inferior
FDA Commissioner’s Rx For US Biosimilars Market: Reform Contracting Practices And Payment Models
Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts
FDA Biologic Transition Plan Creates 'Dead Zone' For Applications, Sponsors Fear

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123802

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel